Biopharmaceuticals Growth Lonza Increases Single-Use Manufacturing Capacity at Slough (UK) Facility
Lonza adds two 1000L single-use bioreactor systems to its current mammalian-based pharmaceuticals manufacturing capacity. Customers are promised increased service flexibility.
Basel/Switzerland – Swiss multinational, chemicals and biotechnology company, Lonza, has announced increased production capacity for mammalian-based pharmaceuticals at its Slough (UK) facility. Two 1000L single-use bioreactors are expected to meet the heightened demand for biopharmaceutical development and clinical manufacturing services. The installation of the units is not anticipated to interrupt current operations. The additional manufacturing capacity for mammalian-based pharmaceuticals is already available to customers.
Lonza’s cGMP facility in Slough is focused on the manufacture of therapeutic grade monoclonal antibodies and recombinant proteins, using small to mid-scale fed-batch suspension culture of mammalian cell cultures. The addition of two bioreactors continues the implementation of single-use technologies at the Slough site and is intended to complement existing single-use equipment for both seed train systems and downstream processing, including chromatography, filtration and ultrafiltration unit operations. Furthermore, the new reactors are equipped with controllers that enable parallel reactor operations and expanded process capabilities with flexible operating scales and bioreactor types.
The Slough capacity upgrade follows in line with an expansion trend in the Lonza Group over the past few years.